Nektar Therapeutics

Nektar Therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. Nektar also partners with the top biopharmaceutical companies to bring new products to market. To date, Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.
Company Growth (employees)
Type
Public
HQ
San Francisco, US
Founded
1990
Size (employees)
468 (est)-24%
Website
nektar.com
Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, US

Key People at Nektar Therapeutics

Robert Chess

Robert Chess

Chairman of the Board
Jillian B. Thomsen

Jillian B. Thomsen

Senior Vice President, Finance and Chief Accounting Officer
Dorian Hirth

Dorian Hirth

Senior Vice President, Human Resources and Facilities Operations
Timothy A. Riley

Timothy A. Riley

Senior Vice President, Technology Assessment and Quality Assurance

Nektar Therapeutics Office Locations

Nektar Therapeutics has offices in San Francisco, Huntsville and Hyderabad
San Francisco, US (HQ)
455 Mission Bay Boulevard South
Hyderabad, IN
Sy.Nos.101/2 Genome Valley Lalgadi Malakpet Shameerpet Mandal Rangareddy District Hyderabad
Huntsville, US
1112 Church Street

Nektar Therapeutics Data and Metrics

Nektar Therapeutics Financial Metrics

Nektar Therapeutics's revenue was reported to be $165.4 m in FY, 2016
Numbers are in $, USD

Revenue (FY, 2016)

165.4 m

Revenue growth (FY, 2015 - FY, 2016), %

(28%)

Gross profit (FY, 2016)

135.2 m

Gross profit margin (FY, 2016), %

82%

Net income (FY, 2016)

(153.5 m)

EBIT (FY, 2016)

(112.9 m)

Market capitalization (23-May-2017)

3.1 b

Closing share price (23-May-2017)

19.3

Cash (31-Dec-2016)

59.6 m
Nektar Therapeutics's current market capitalization is $3.1 b.
Numbers are in $, USDFY, 2013FY, 2014Y, 2015FY, 2016

Revenue

148.9 m200.7 m230.8 m165.4 m

Revenue growth, %

35%15%(28%)

Cost of goods sold

38.5 m28.5 m34.1 m30.2 m

Gross profit

110.4 m172.2 m196.7 m135.2 m

Gross profit Margin, %

74%86%85%82%

Operating expense total

230.5 m188.7 m260.2 m278.3 m

EBIT

(120.1 m)(16.5 m)(29.4 m)(112.9 m)

EBIT margin, %

(81%)(8%)(13%)(68%)

Interest expense

18.5 m17.9 m18.3 m22.5 m

Interest income

732 k814 k

Pre tax profit

(159.8 m)

Income tax expense

2.2 m(512 k)506 k876 k

Net Income

(162 m)(53.9 m)(81.2 m)(153.5 m)
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

39.1 m12.4 m55.6 m59.6 m

Accounts Receivable

Inventories

13.5 m13 m11.3 m11.1 m

Current Assets

257.9 m288.2 m350.1 m426.3 m

PP&E

67 m70.4 m71.3 m65.6 m

Goodwill

76.5 m76.5 m76.5 m76.5 m

Total Assets

434.5 m441.6 m502.1 m568.9 m

Accounts Payable

9.1 m2.7 m2.4 m2.8 m

Current Liabilities

98.2 m64 m61.2 m72.2 m

Additional Paid-in Capital

1.6 b1.8 b1.9 b2.1 b

Retained Earnings

(1.7 b)(1.8 b)(1.9 b)(2 b)

Total Equity

(89.9 m)36.3 m6.4 m88.1 m

Financial Leverage

-4.8 x12.2 x78.1 x6.5 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(162 m)(53.9 m)(81.2 m)(153.5 m)

Depreciation and Amortization

14.3 m12.9 m12.9 m15.4 m

Accounts Receivable

3.6 m(1.4 m)(16 m)4.3 m

Inventories

4.8 m500 k1.6 m237 k

Accounts Payable

6.2 m(6.4 m)(412 k)518 k

Cash From Operating Activities

(38.5 m)(142 m)(73.1 m)(117 m)

Purchases of PP&E

(4.1 m)(10 m)(11.2 m)(6.4 m)

Cash From Investing Activities

49.9 m(37.6 m)(14.3 m)(82.4 m)

Cash From Financing Activities

2.2 m153 m130.8 m203.6 m

Interest Paid

17.6 m17.4 m20.2 m20.6 m

Income Taxes Paid

1 m964 k860 k757 k
Numbers are in $, USDY, 2016

Revenue/Employee

269 k

Financial Leverage

6.5 x

Nektar Therapeutics Market Value History

Nektar Therapeutics Online and Social Media Presence

Nektar Therapeutics Company Life and Culture

You may also be interested in